• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Croatia Pharmaceuticals and Healthcare Report Q2 2012 - Product Image

Croatia Pharmaceuticals and Healthcare Report Q2 2012

  • ID: 2077824
  • February 2012
  • Region: Croatia
  • 88 Pages
  • Business Monitor International

FEATURED COMPANIES

  • Belupo
  • GlaxoSmithKline
  • Krka
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

BMI View: Based on Croatia’s deteriorating macroeconomic outlook, combined with our expectations that the new Kukuriku coalition government will pursue more severe austerity measures and the fact the Croatian Institute For Health Insurance (HZZO) announced huge – though probably not achievable – cuts to its Q112 healthcare budget, BMI has downgraded the 2012 and 2013 outlooks for Croatia’s pharmaceutical, healthcare and medical device market. We expect further cost-cutting measures to be announced in the coming months. Croatia’s pharmaceutical market will continue to be a modest prospect for foreign companies despite some opportunities provided by the operating environment improvements expected in the leadup to EU membership.

Headline Expenditure Projections

- Pharmaceuticals: HRK7.16bn (US$1.34bn) in 2011 to HRK6.94bn (US$1.29bn) in 2012; - 3.1% in local currency and -3.7% in US dollar terms. Forecast down significantly from Q112 due to economic factors and analyst modification.

- Healthcare: HRK27.10bn (US$5.07bn) in 2011 to HRK26.19bn (US$4.86bn) in 2011; -3.4% in local currency and -4.0% in US dollar terms. Forecast down significantly READ MORE >

FEATURED COMPANIES

  • Belupo
  • GlaxoSmithKline
  • Krka
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

Executive Summary
Croatia Pharmaceuticals Industry SWOT
Croatia Political SWOT
Croatia Economic SWOT
Croatia Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Central And Eastern Europe Risk/Reward Ratings, Q212
Rewards
Risks
Croatia – Market Summary
Regulatory Regime
Pharmaceutical Advertising
Intellectual Property Regime
Pricing Regime
Reimbursement Regime
OTC Regulations
Industry Trends And Developments
Epidemiology
Healthcare Provision
Healthcare Expenditure
Table: Overview Of Prescribing Patterns, 1999-2009
Healthcare Debts
Healthcare Reform
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2008-2016
Healthcare Market Forecast
Table: Healthcare Expenditure Indicators 2008-2016
Table: Healthcare Governmental Indicators 2008-2016
Table: Healthcare Private Indicators 2008-2016
Key Growth Factors – Macroeconomic
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2008-2016
Patented Drug Market Forecast
Table: Patented Drug Market Indicators 2008-2016
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2008-2016
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2008-2016
Medical Device Market Forecast
Table: Medical Devices Sales Indicators 2008-2016
Pharmaceutical Trade Forecast
Table: Exports and Imports Indicators 2008-2016
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Pharmaceutical Industry
Table: Croatia – Top 10 Medicines by Value Sales
Domestic Pharmaceutical Industry
Table: Croatian Pharmaceutical Manufacturers
Foreign Pharmaceutical Industry
Recent Company Activity
Pharmaceutical Wholesale
Pharmaceutical Retail
Company Profiles
Indigenous Company Profiles
PLIVA (Teva Pharmaceuticals)
Belupo
Jadran Galenski Laboratorij (JGL)
Foreign Company Profiles
GlaxoSmithKline
Pfizer
Sanofi
Novartis
Merck & Co
Krka
Country Snapshot: Croatia Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2000-2003
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 1999-2004
Table: Consumer Expenditure, 2000-2010 (US$)
Table: Average Annual Wages, 2000-2010
Glossary
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components

- Indigenous Company Profiles
- PLIVA (Teva Pharmaceuticals)
- Belupo
- Jadran Galenski Laboratorij (JGL)
- GlaxoSmithKline
- Pfizer
- Sanofi
- Novartis
- Merck & Co
- Krka

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos